Abstract
Abstract
Purpose
The aim of this study was to understand how coating with a pulmonary surfactant, namely Alveofact, affects the physicochemical parameters as well as in vitro behavior of polyethylenimine (PEI) polyplexes for pulmonary siRNA delivery.
Methods
Alveofact-coated polyplexes were prepared at different Alveofact:PEI coating ratios and analyzed in terms of size, PDI and zeta potential as well as morphology by transmission electron microscopy. The biological behavior was evaluated in a lung epithelial cell line regarding cell viability, cellular uptake via flow cytometry and gene downregulation by qRT-PCR. Furthermore, a 3D ALI culture model was established to test the mucus diffusion and cellular uptake by confocal microscopy as well as gene silencing activity by qRT-PCR.
Results
After optimizing the coating process by testing different Alveofact:PEI coating ratios, a formulation with suitable parameters for lung delivery was obtained. In lung epithelial cells, Alveofact-coated polyplexes were well tolerated and internalized. Furthermore, the coating improved the siRNA-mediated gene silencing efficiency. Alveofact-coated polyplexes were then tested on a 3D air-liquid interface (ALI) culture model that, by expressing tight junctions and secreting mucus, resembles important traits of the lung epithelium. Here, we identified the optimal Alveofact:PEI coating ratio to achieve diffusion through the mucus layer while retaining gene silencing activity. Interestingly, the latter underlined the importance of establishing appropriate in vitro models to achieve more consistent results that better predict the in vivo activity.
Conclusion
The addition of a coating with pulmonary surfactant to polymeric cationic polyplexes represents a valuable formulation strategy to improve local delivery of siRNA to the lungs.
Graphical Abstract
Funder
H2020 Excellent Science
Ludwig-Maximilians-Universität München
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference43 articles.
1. Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong X bo. The growth of siRNA-based therapeutics: Updated clinical studies Biochem Pharmacol 2021;189:114432.
2. Lamb YN. Inclisiran: first approval. Drugs [Internet]. 2021;81(3):389–95. Available from: https://doi.org/10.1007/s40265-021-01473-6.
3. Tieu T, Wei Y, Cifuentes-Rius A, Voelcker NH. Overcoming barriers: clinical translation of siRNA nanomedicines. Adv Ther. 2021;4(9):1–24.
4. Vicentini FTMDC, Borgheti-Cardoso LN, Depieri LV, De MacEdo MD, Abelha TF, Petrilli R, et al. Delivery systems and local administration routes for therapeutic siRNA. Pharm Res. 2013;30(4):915–31.
5. Mendes BB, Conniot J, Avital A, Yao D, Jiang X, Zhou X, et al. Nanodelivery of nucleic acids. Nat Rev Methods Prim. 2(1):1–21. https://doi.org/10.1038/s43586-022-00104-y.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献